{
    "info": {
        "nct_id": "NCT04666038",
        "official_title": "A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)",
        "inclusion_criteria": "* Confirmed diagnosis of CLL/SLL requiring therapy as defined by iwCLL 2018 criteria.\n* Previously treated with a covalent BTK inhibitor.\n* Eastern Cooperative Oncology Group (ECOG) 0-2.\n* Absolute neutrophil count ≥ 0.75 × 10^9/L without granulocyte-colony-stimulating factor support, or ≥ 0.50 × 10^9/L in patients with documented bone marrow involvement considered to impair hematopoiesis. Granulocyte-colony-stimulating factor support is permitted in patients with documented bone marrow involvement.\n* Hemoglobin ≥ 8 g/dL or ≥ 6 g/dL in patients with documented bone marrow involvement considered to impair hematopoiesis. Transfusion support is permitted in patients with bone marrow involvement.\n* Platelets ≥ 50 × 10^9/L. If an investigator has chosen bendamustine/rituximab as the Arm B treatment, platelets must be ≥ 75 × 10^9/L. Patients may enroll below these thresholds if the Investigator determines the cytopenia is related to bone marrow involvement considered to impair hematopoiesis. Patients with a platelet count < 30 x 10^9/L are excluded.\n* AST and ALT ≤ 3.0 x upper limit of normal (ULN).\n* Total bilirubin ≤ 1.5 x ULN.\n* Estimated creatinine clearance of ≥ 30 mL/min.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Known or suspected Richter's transformation at any time preceding enrollment.\n* Known or suspected history of central nervous system (CNS) involvement by CLL/SLL.\n* Ongoing drug-induced liver injury.\n* Active uncontrolled auto-immune cytopenia.\n* Significant cardiovascular disease.\n* History of allogeneic or stem cell transplantation (SCT) or chimeric antigen receptor-modified T cells (CAR-T) therapy within the past 60 days.\n* Active hepatitis B or hepatitis C.\n* Known active cytomegalovirus (CMV) infection.\n* Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.\n* Known Human Immunodeficiency Virus (HIV) infection, regardless of CD4 count.\n* Clinically significant active malabsorption syndrome or inflammatory bowel disease\n* Prior exposure to non-covalent (reversible) BTK inhibitor.\n* Patients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist.\n* Current treatment with strong cytochrome P450 (CYP) 3A4 (CYP3A4) inhibitors or inducers.\n* Vaccination with a live vaccine within 28 days prior to randomization.\n* Patients with the following hypersensitivity:\n\n  1. Known hypersensitivity, including anaphylaxis, to any component or excipient of LOXO-305. For patients planned to receive idelalisib, known hypersensitivity, including anaphylaxis, to any component or excipient of idelalisib. For patients planned to receive bendamustine, known hypersensitivity, including anaphylaxis, to any component or excipient of bendamustine.\n  2. Prior significant hypersensitivity to rituximab.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Confirmed diagnosis of CLL/SLL requiring therapy as defined by iwCLL 2018 criteria.",
            "criterions": [
                {
                    "exact_snippets": "Confirmed diagnosis of CLL/SLL",
                    "criterion": "CLL/SLL diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring therapy as defined by iwCLL 2018 criteria",
                    "criterion": "need for therapy (per iwCLL 2018 criteria)",
                    "requirements": [
                        {
                            "requirement_type": "requirement for therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "definition standard",
                            "expected_value": "iwCLL 2018 criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previously treated with a covalent BTK inhibitor.",
            "criterions": [
                {
                    "exact_snippets": "Previously treated with a covalent BTK inhibitor.",
                    "criterion": "prior treatment with covalent BTK inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) 0-2.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) 0-2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count ≥ 0.75 × 10^9/L without granulocyte-colony-stimulating factor support, or ≥ 0.50 × 10^9/L in patients with documented bone marrow involvement considered to impair hematopoiesis. Granulocyte-colony-stimulating factor support is permitted in patients with documented bone marrow involvement.",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count ≥ 0.75 × 10^9/L without granulocyte-colony-stimulating factor support",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.75,
                                "unit": "× 10^9/L"
                            }
                        },
                        {
                            "requirement_type": "granulocyte-colony-stimulating factor support",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 0.50 × 10^9/L in patients with documented bone marrow involvement considered to impair hematopoiesis",
                    "criterion": "absolute neutrophil count (in patients with documented bone marrow involvement considered to impair hematopoiesis)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "× 10^9/L"
                            }
                        },
                        {
                            "requirement_type": "bone marrow involvement impairing hematopoiesis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin ≥ 8 g/dL or ≥ 6 g/dL in patients with documented bone marrow involvement considered to impair hematopoiesis. Transfusion support is permitted in patients with bone marrow involvement.",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 8 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 6 g/dL in patients with documented bone marrow involvement considered to impair hematopoiesis",
                    "criterion": "hemoglobin in patients with documented bone marrow involvement considered to impair hematopoiesis",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AST and ALT ≤ 3.0 x upper limit of normal (ULN).",
            "criterions": [
                {
                    "exact_snippets": "AST ... ≤ 3.0 x upper limit of normal (ULN)",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT ≤ 3.0 x upper limit of normal (ULN)",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin ≤ 1.5 x ULN.",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤ 1.5 x ULN",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets ≥ 50 × 10^9/L. If an investigator has chosen bendamustine/rituximab as the Arm B treatment, platelets must be ≥ 75 × 10^9/L. Patients may enroll below these thresholds if the Investigator determines the cytopenia is related to bone marrow involvement considered to impair hematopoiesis. Patients with a platelet count < 30 x 10^9/L are excluded.",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥ 50 × 10^9/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If an investigator has chosen bendamustine/rituximab as the Arm B treatment, platelets must be ≥ 75 × 10^9/L",
                    "criterion": "platelet count (Arm B: bendamustine/rituximab)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients may enroll below these thresholds if the Investigator determines the cytopenia is related to bone marrow involvement considered to impair hematopoiesis",
                    "criterion": "cytopenia etiology",
                    "requirements": [
                        {
                            "requirement_type": "cause",
                            "expected_value": "bone marrow involvement considered to impair hematopoiesis"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with a platelet count < 30 x 10^9/L are excluded",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Estimated creatinine clearance of ≥ 30 mL/min.",
            "criterions": [
                {
                    "exact_snippets": "Estimated creatinine clearance of ≥ 30 mL/min.",
                    "criterion": "estimated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Known Human Immunodeficiency Virus (HIV) infection, regardless of CD4 count.",
            "criterions": [
                {
                    "exact_snippets": "Known Human Immunodeficiency Virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "regardless of CD4 count",
                    "criterion": "CD4 count",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "any"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant cardiovascular disease.",
            "criterions": [
                {
                    "exact_snippets": "Significant cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with the following hypersensitivity:",
            "criterions": [
                {
                    "exact_snippets": "Patients with the following hypersensitivity",
                    "criterion": "hypersensitivity",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Prior significant hypersensitivity to rituximab.",
            "criterions": [
                {
                    "exact_snippets": "Prior significant hypersensitivity to rituximab",
                    "criterion": "hypersensitivity to rituximab",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist.",
            "criterions": [
                {
                    "exact_snippets": "Patients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist",
                    "criterion": "therapeutic anticoagulation with warfarin or another Vitamin K antagonist",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active hepatitis B or hepatitis C.",
            "criterions": [
                {
                    "exact_snippets": "Active hepatitis B",
                    "criterion": "hepatitis B",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Active ... hepatitis C",
                    "criterion": "hepatitis C",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known or suspected Richter's transformation at any time preceding enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Known or suspected Richter's transformation at any time preceding enrollment.",
                    "criterion": "Richter's transformation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active cytomegalovirus (CMV) infection.",
            "criterions": [
                {
                    "exact_snippets": "Known active cytomegalovirus (CMV) infection",
                    "criterion": "cytomegalovirus (CMV) infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "awareness/status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of allogeneic or stem cell transplantation (SCT) or chimeric antigen receptor-modified T cells (CAR-T) therapy within the past 60 days.",
            "criterions": [
                {
                    "exact_snippets": "History of allogeneic or stem cell transplantation (SCT) ... within the past 60 days.",
                    "criterion": "allogeneic or stem cell transplantation (SCT)",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 60,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... chimeric antigen receptor-modified T cells (CAR-T) therapy within the past 60 days.",
                    "criterion": "chimeric antigen receptor-modified T cells (CAR-T) therapy",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 60,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current treatment with strong cytochrome P450 (CYP) 3A4 (CYP3A4) inhibitors or inducers.",
            "criterions": [
                {
                    "exact_snippets": "Current treatment with strong cytochrome P450 (CYP) 3A4 (CYP3A4) inhibitors or inducers.",
                    "criterion": "current treatment with strong CYP3A4 inhibitors or inducers",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant active malabsorption syndrome or inflammatory bowel disease",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant active malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically significant ... inflammatory bowel disease",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known or suspected history of central nervous system (CNS) involvement by CLL/SLL.",
            "criterions": [
                {
                    "exact_snippets": "Known or suspected history of central nervous system (CNS) involvement by CLL/SLL.",
                    "criterion": "central nervous system (CNS) involvement by CLL/SLL",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "suspicion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active uncontrolled auto-immune cytopenia.",
            "criterions": [
                {
                    "exact_snippets": "Active uncontrolled auto-immune cytopenia",
                    "criterion": "auto-immune cytopenia",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior exposure to non-covalent (reversible) BTK inhibitor.",
            "criterions": [
                {
                    "exact_snippets": "Prior exposure to non-covalent (reversible) BTK inhibitor.",
                    "criterion": "non-covalent (reversible) BTK inhibitor exposure",
                    "requirements": [
                        {
                            "requirement_type": "prior exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Known hypersensitivity, including anaphylaxis, to any component or excipient of LOXO-305. For patients planned to receive idelalisib, known hypersensitivity, including anaphylaxis, to any component or excipient of idelalisib. For patients planned to receive bendamustine, known hypersensitivity, including anaphylaxis, to any component or excipient of bendamustine.",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity, including anaphylaxis, to any component or excipient of LOXO-305",
                    "criterion": "hypersensitivity to LOXO-305 components or excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "For patients planned to receive idelalisib, known hypersensitivity, including anaphylaxis, to any component or excipient of idelalisib",
                    "criterion": "hypersensitivity to idelalisib components or excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "For patients planned to receive bendamustine, known hypersensitivity, including anaphylaxis, to any component or excipient of bendamustine",
                    "criterion": "hypersensitivity to bendamustine components or excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ongoing drug-induced liver injury.",
            "criterions": [
                {
                    "exact_snippets": "Ongoing drug-induced liver injury",
                    "criterion": "drug-induced liver injury",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "ongoing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Vaccination with a live vaccine within 28 days prior to randomization.",
            "criterions": [
                {
                    "exact_snippets": "Vaccination with a live vaccine within 28 days prior to randomization.",
                    "criterion": "live vaccine vaccination",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to randomization"
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.",
            "criterions": [
                {
                    "exact_snippets": "Active uncontrolled systemic bacterial ... infection",
                    "criterion": "systemic bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Active uncontrolled systemic viral ... infection",
                    "criterion": "systemic viral infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Active uncontrolled systemic fungal ... infection",
                    "criterion": "systemic fungal infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Active uncontrolled systemic parasitic infection",
                    "criterion": "systemic parasitic infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}